This biotech has a one-of-a-kind colon cancer blood test. Shares broke out of a base on recent news.

Guardant Health’s latest analyst update keeps the stock’s price target unchanged, indicating that current expectations remain steady for now. In the following sections, you will see how to track this ...

Shares of diagnostics company Guardant Health (NASDAQ:GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares of company stock, a transaction valued at over $5 million.

Guardant Health (NASDAQ: GH) is on the rise, in more ways than one. Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several key ...

Shares of Guardant Health (NASDAQ: GH) rocketed 28% higher on Thursday after the precision oncology company reported outstanding growth metrics across its key product lines. A doctor is reviewing ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of ...

Guardant's oncology and screening businesses are expanding at a rapid pace. New partnerships should drive further gains. Guardant's third-quarter revenue soared by 39% year over year to $265.2 million ...